{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Restrict the search for
l-glutamine
to a specific field?
Status:
Investigational
Source:
INN:bemnifosbuvir [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT04337879: Phase 1/Phase 2 Interventional Unknown status Advanced Colorectal Cancer
(2020)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00978211: Phase 2 Interventional Completed Neuroendocrine Tumors
(1997)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Edotreotide (SMT487) is a DOTA-containing somatostatin analog. Edotreotide binds with high affinity to somatostatin receptors. Somatostatin receptors are predominantly overexpressed by neuroendocrine tumors. On 15 September 2016, the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending granting a marketing authorisation for the orphan medicine edotreotide (SomaKit-TOC) intended for use in Positron Emission Tomography (PET) imaging in adult patients with gastro-enteropancreatic neuroendocrine tumours (GEP-NETs). SomaKit TOC was designated as an orphan medicinal product on 19 March 2015. 68Ga-Edotreotide, distributed under the brand name TOCscan® (Sogacin® in Austria/ France), is the companion diagnostic in ITM´s theranostic approach for the treatment of neuroendocrine tumors (NETs). N.c.a. 177Lu-Edotreotide is known as an innovative Targeted Radionuclide Therapy agent with favorable safety profile and promising efficacy. N.c.a. 177Lu-Edotreotide received an Orphan Designation as treatment of gastro-entero-pancreatic neuroendocrine tumors (GEP-NET) based on academic clinical Phase II data suggesting a significant benefit (substantially improved progression-free survival, PFS).
Status:
Investigational
Source:
NCT03748199: Phase 1/Phase 2 Interventional Completed Cystic Fibrosis
(2018)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00951743: Phase 2 Interventional Unknown status HIV Infections
(2009)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Targets:
DAPTA (D-ala-peptide T-amide) is a synthetic peptide that prevents HIV entry by blocking binding of HIV gp120 protein with CCR5 receptor. In a small clinical study of internasal formulation of DAPTA in long-term infected HIV patients, administration of DAPTA led to decrease in the amount of virus isolated from white blood cells, an increase in gamma-interferon secreting T-cells in the absense of drug-related toxicity. In another clinical study DAPTA in combination with antiretroviral therapy reduced the peripheral (plasma and serum) viral load, but did not reduce the CSF viral load.
Status:
Investigational
Source:
Psychopharmacol Bull. 1991;27(3):237-45.: Phase 2 Human clinical trial Completed Acquired Immunodeficiency Syndrome/psychology
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT02837900: Phase 2 Interventional Completed Knee Osteoarthritis
(2016)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
INN:enbezotinib [INN]
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT00278980: Phase 2 Interventional Completed Diabetes Mellitus, Type 1
(2003)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Status:
Investigational
Source:
NCT01327495: Phase 2/Phase 3 Interventional Completed Healthy
(2011)
Source URL:
Class (Stereo):
CHEMICAL (ABSOLUTE)
Merrion Pharmaceuticals was developing an oral tablet formulation of acyline, a gonadotropin-releasing hormone (GnRH) antagonist, referred to as MER 104. MER-104 effectively suppresses luteinizing hormone (LH) and follicle-stimulating hormone (FSH) secretion in man. Acyline has been investigated for the prevention and treatment of hypogonadism and contraception. Injectable forms have been administered successfully in man in Phase II studies as part of a potential contraceptive regimen. MER-104 is an enteric coated acyline tablet developed by Merrion Pharmaceuticals using GIPET™ I technology to enable the oral administration of this decapeptide. The development of acyline appears to have been discontinued.
